Brief: Aridis Pharmaceuticals Receives Funding To Evaluate Inhaled Monoclonal Antibodies To Block Influenza And Sars-Cov-2 Transmission
27/01/2022 11:48
Jan 27 (Reuters) - Aridis Pharmaceuticals Inc ARDS.O :
* ARIDIS PHARMACEUTICALS RECEIVES FUNDING TO EVALUATE
INHALED
MONOCLONAL ANTIBODIES TO BLOCK INFLUENZA AND SARS-COV-2
TRANSMISSION
* ARIDIS PHARMACEUTICALS RECEIVES FUNDING TO EVALUATE
INHALED
MONOCLONAL ANTIBODIES TO BLOCK INFLUENZA AND SARS-COV-2
TRANSMISSION
* ARIDIS PHARMA - FUNDING FROM BILL & MELINDA GATES
FOUNDATION TO
SUPPORT DEVELOPMENT OF ARIDIS' INHALED FORMULATION TECHNOLOGY
Source text for Eikon: ID:nPn5Vfzjza
Further company coverage: ARDS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aridis Pharmaceuticals
See all newsBrief: Aridis Pharmaceuticals Inc - On September 7 Nasdaq Announced That It Would Delist Common Stock Of Co
U.S. STOCKS ON THE MOVE-Pieris Pharma, Microsoft, Energy sector
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
U.S. STOCKS ON THE MOVE-Teladoc Health, NVDIA, Chipotle
U.S. STOCKS ON THE MOVE-Pinterest, Sunrun, Tencent Music